Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
Clinical trial NCT06730126 · RECRUITING
Trial details
- NCT number
- NCT06730126
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-10
- Primary completion
- 2026-12-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.